Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX)

J. von Pawel,K. Park,José Rodrigues Pereira,A. Szczesna,Chih-Teng Yu,V. L. Ganul,Maciej Krzakowski,Jae Kyung Roh,K. Pilz,R. Pirker

Phase III study comparing cisplatin/vinorelbine plus cetuximab versus cisplatin/vinorelbine as first-line treatment for patients with epidermal growth factor (EGFR)-expressing advanced non-small cell lung cancer (NSCLC) (FLEX)

2006

J. von Pawel
K. Park
José Rodrigues Pereira
A. Szczesna
Chih-Teng Yu
V. L. Ganul
Maciej Krzakowski
Jae Kyung Roh
K. Pilz
R. Pirker

7109 Background: Cisplatin plus vinorelbine is a commonly used regimen for first-line therapy of advanced NSCLC, achieving response rates of 20–30% and median survival times of 6 to 11 months (mths...

Keywords:

Epidermal growth factor
Cetuximab
non-small cell lung cancer (NSCLC)
Cisplatin/vinorelbine
Oncology
Internal medicine
Medicine
Cisplatin
first line treatment
Vinorelbine
Regimen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations